Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 6/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7024488 | 1.00 | CTSK (0.55) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL9103792 | 1.00 | CTSK (0.55) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL9103775 | 1.00 | CTSK (0.55) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL9103286 | 0.91 | CTSK (0.52) | CTSKCTSSCTSLATM | |
| SCHEMBL9103298 | 0.91 | CTSK (0.52) | CTSKCTSSCTSLATM | |
| SCHEMBL10270258 | 0.90 | CTSL (0.60) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL9100213 | 0.89 | CTSL (0.57) | CTSKCTSSCTSL | |
| SCHEMBL9100192 | 0.89 | CTSL (0.57) | CTSKCTSSCTSL | |
| SCHEMBL9943827 | 0.89 | CTSL (0.57) | CTSKCTSSCTSL | |
| SCHEMBL4275633 | 0.87 | ATM (0.55) | CTSKCTSSCTSLPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464368-A1 | CATHEPSIN C INHIBITORS | Glaxo Group Limited (GB) | 2012-06-20 | — | — | EP | disclosed |
| WO-2002048097-A9 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INT INC (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | DENDREON CORPORATION | 2002-08-08 | — | — | US | disclosed |
| WO-2002048097-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INTERNATIONAL, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | CAT, CTSA, CTRL | CTSK 17/4885CTSS 5/4885CTSL 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.